Novo Nordisk Logo

Novo Nordisk

Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.

NOVO | CO

Overview

Corporate Details

ISIN(s):
DK0062498333 (+1 more)
LEI:
549300DAQ1CVT6CXN342
Country:
Denmark
Address:
Novo Alle 1, 2880 Bagsværd
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Novo Nordisk is a global healthcare company that discovers, develops, and manufactures innovative biological medicines and therapeutic devices. With a focus on driving change to defeat serious chronic diseases, the company's primary treatment areas include diabetes, obesity, and rare blood and endocrine disorders. Leveraging over 90 years of innovation, Novo Nordisk provides pharmaceutical products and services to patients worldwide, aiming to make its treatments accessible and improve health outcomes.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Novo Nordisk and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-10 07:00
Regulatory News Service
English 11.2 KB
2025-09-10 07:00
Earnings Release
English 151.5 KB
2025-08-19 13:37
Director's Dealing
English 17.4 KB
2025-08-19 13:37
Director's Dealing
English 144.5 KB
2025-08-12 14:25
Director's Dealing
English 144.4 KB
2025-08-12 14:25
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 144.5 KB
2025-08-07 17:30
Director's Dealing
English 159.1 KB
2025-08-07 17:30
Director's Dealing
English 30.5 KB
2025-08-06 07:30
Earnings Release
English 1.4 MB
2025-08-06 07:30
Earnings Release
English 11.9 KB
2025-07-29 13:35
Board/Management Information
English 12.0 KB
2025-07-29 13:35
Board/Management Information
English 176.8 KB
2025-07-29 13:01
Earnings Release
English 167.4 KB

Automate Your Workflow. Get a real-time feed of all Novo Nordisk filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Novo Nordisk via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden ORX
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland ORNAV
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan 4578
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom OCTHF
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany PA8

Talk to a Data Expert

Have a question? We'll get back to you promptly.